Business Wire

PUDO-ROBOTICS

Share
Pudu Robotics Announces Newly Released Puductor2 to Improve Public Health Safety

Pudo Robotics announced today the release of Puductor2, a technology-based, anti-pandemic robot. This newly designed intelligent robot has two disinfection modes of ultra-dry mist and UV-C ultraviolet ray, featuring large domain of walk, long detection distance, high positioning accuracy, and stronger environmental adaptability. Puductor2 further expands its scope of application while enhancing its disinfection and killing ability, to include such locations as government halls, schools, medical institutions, waiting rooms, airports, subways, banks and other public places.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201128005104/en/

According to the BBC news, the coronavirus bounced back in late October in European countries. In 10 days, the cumulative confirmed cases in the 53 European member states of the World Health Organization (WHO) have soared from 6 million to more than 7 million .

Against the backdrop of the pandemic, European countries have adopted methods such as limiting the number of gatherings, early curfews, and lockdowns to fight this new battle without affecting the economy. In fact, all fail to keep the virus under better control. Some experts suggest that Europe and the United States can learn and follow China's anti-pandemic approaches, that is, technology-based anti-pandemic measures. For example, in the hospitals and quarantine points in Wuhan, China, where witnessed the most severe virus in early 2020, intelligent robots were used to disinfect the pandemic areas and deliver daily medical supplies, such as delivering food, water, medicine and other necessities to patients. Under serious shortage of medical staff and medical supplies, the participation of robots in the fight against the pandemic will not only improve work efficiency and reduce the loss of medical supplies, but also substantially reduce contact between personnel, thus effectively slowing the spread of the pandemic.

Among technical anti-pandemic robots, the most common one is "Pudubot", a product from the Chinese company - Pudu Robotics. It is understood that Pudu Robotics, headquartered in Shenzhen, China's tech capital, serves as a national high-tech enterprise home to R&D, design, production and sales of commercial service robots. Its distribution service robots "Pudubot", "Bellabot", and "Holabot" have been widely introduced in the catering industry, and cooperation with domestic catering giants such as Haidilao have been successively reached. In order to support the fight against the pandemic, the ultra-dry mist disinfection robot Puductor developed and produced by Pudu Robotics is also widely used in hotels, restaurants, airports, medical institutions, government halls, etc., around the world for disinfection. It is reported that Puductor adopts the ultra-dry mist disinfection technology, which can capture harmful microorganisms in the air and quickly disinfect and kill bacteria and viruses, such as the currently raging COVID-19, with a sterilizing rate of 99.99%.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release

Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc

Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release

SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f

Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release

Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr

IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release

Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston

Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 21:50:00 CET | Press release

A R$490 million investment expands the supply of raw material used in the production of absorbent items Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye